Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in patients taking these medications. The drugs may ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

A new study found weight loss injections may help reduce the risk of dementia and stroke in people who are obese and have ...

Ozempic and the brain As much as GLP-1 agonists like Ozempic and Wegovy have gained cultural relevance as weight-loss drugs, they were originally approved to treat diabetes. The GLP-1 receptor in ...

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared to those on other medications.

Semaglutide, found in Ozempic and Wegovy, may lower dementia risk in diabetics, with stronger effects in older adults and women. The findings are based on data from nearly 1.7 million people.

Weight loss jabs such as Wegovy and Mounjaro may offer a protective effect against dementia and stroke, according to a new ...

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...